|
GB1381872A
(en)
*
|
1971-06-22 |
1975-01-29 |
Fisons Ltd |
Pharmaceutical compositions for inhalation
|
|
GB1410588A
(en)
*
|
1971-08-10 |
1975-10-22 |
Fisons Ltd |
Composition
|
|
DE2332663C2
(de)
*
|
1973-06-23 |
1986-07-31 |
Schering AG, 1000 Berlin und 4709 Bergkamen |
Verwendung von Kortikoid-Wirkstoffen zur Inhalationstherapie
|
|
DE2535258C2
(de)
*
|
1974-08-10 |
1993-06-03 |
Fisons Plc, Ipswich, Suffolk |
Inhalierbares Medikament in Pelletform
|
|
US4161516A
(en)
*
|
1975-07-25 |
1979-07-17 |
Fisons Limited |
Composition for treating airway disease
|
|
FI770215A7
(en:Method)
*
|
1976-01-30 |
1977-07-31 |
Fisons Ltd |
|
|
CY1333A
(en)
*
|
1980-04-30 |
1986-10-24 |
Fisons Ltd |
Pharmaceutical compositions containing cromoglycates
|
|
BE891013A
(fr)
*
|
1980-11-05 |
1982-05-05 |
Fisons Ltd |
Compositions pharmaceutique
|
|
JPS59163313A
(ja)
*
|
1983-03-09 |
1984-09-14 |
Teijin Ltd |
経鼻投与用ペプチドホルモン類組成物
|
|
JP2770970B2
(ja)
*
|
1987-04-09 |
1998-07-02 |
フアイソンズ・ピーエルシー |
ペンタミジンを含有する医薬組成物
|
|
US5204113A
(en)
*
|
1987-04-09 |
1993-04-20 |
Fisons Plc |
Pharmaceutical compositions containing pentamidine
|
|
DE4140689B4
(de)
*
|
1991-12-10 |
2007-11-22 |
Boehringer Ingelheim Kg |
Inhalationspulver und Verfahren zu ihrer Herstellung
|
|
DE69330672T2
(de)
*
|
1992-06-12 |
2002-06-27 |
Teijin Ltd., Osaka |
Pharmazeutische zubereitung zur anwendung in den atemwegen
|
|
US6632456B1
(en)
|
1993-06-24 |
2003-10-14 |
Astrazeneca Ab |
Compositions for inhalation
|
|
US5830853A
(en)
|
1994-06-23 |
1998-11-03 |
Astra Aktiebolag |
Systemic administration of a therapeutic preparation
|
|
US6794357B1
(en)
|
1993-06-24 |
2004-09-21 |
Astrazeneca Ab |
Compositions for inhalation
|
|
IS1736B
(is)
|
1993-10-01 |
1999-12-30 |
Astra Ab |
Aðferð og tæki sem stuðla að aukinni samloðun agna
|
|
SK283569B6
(sk)
*
|
1993-10-01 |
2003-09-11 |
Astra Aktiebolag |
Spôsob spracovania jemne deleného práškového liečiva, zariadenie na vykonávanie tohto spôsobu a aglomeráty vyrobené týmto spôsobom
|
|
NL9301851A
(nl)
*
|
1993-10-26 |
1995-05-16 |
Cordis Europ |
Cryo-ablatie catheter.
|
|
GB9322014D0
(en)
|
1993-10-26 |
1993-12-15 |
Co Ordinated Drug Dev |
Improvements in and relating to carrier particles for use in dry powder inhalers
|
|
GB9404945D0
(en)
|
1994-03-15 |
1994-04-27 |
Glaxo Group Ltd |
Pharmaceutical composition
|
|
US6102036A
(en)
*
|
1994-04-12 |
2000-08-15 |
Smoke-Stop |
Breath activated inhaler
|
|
US6165976A
(en)
|
1994-06-23 |
2000-12-26 |
Astra Aktiebolag |
Therapeutic preparation for inhalation
|
|
DE4425255A1
(de)
|
1994-07-16 |
1996-01-18 |
Asta Medica Ag |
Formulierung zur inhalativen Applikation
|
|
PT806945E
(pt)
|
1994-12-22 |
2003-09-30 |
Astrazeneca Ab |
Preparacao terapeutica para inalacao que contem a hormona paratiroide, hpt
|
|
WO1996019198A1
(en)
|
1994-12-22 |
1996-06-27 |
Astra Aktiebolag |
Aerosol drug formulations
|
|
US6524557B1
(en)
|
1994-12-22 |
2003-02-25 |
Astrazeneca Ab |
Aerosol formulations of peptides and proteins
|
|
GB9501841D0
(en)
|
1995-01-31 |
1995-03-22 |
Co Ordinated Drug Dev |
Improvements in and relating to carrier particles for use in dry powder inhalers
|
|
DE69825995T2
(de)
*
|
1997-05-27 |
2005-09-08 |
Direct-Haler A/S |
Inhalator für pulverförmige medikamente
|
|
ID27345A
(id)
|
1998-08-18 |
2001-04-05 |
Univ California |
Pencegahan produksi lendir jalan udara dengan antagonis egf-r
|
|
US7354894B2
(en)
*
|
1998-08-18 |
2008-04-08 |
The Regents Of The University Of California |
Preventing airway mucus production by administration of EGF-R antagonists
|
|
ATE294608T1
(de)
|
1999-06-05 |
2005-05-15 |
Innovata Biomed Ltd |
Verabreichungsystem für medikamente
|
|
ITMI991582A1
(it)
|
1999-07-16 |
2001-01-16 |
Chiesi Farma Spa |
Polveri costituite da particelle aventi la superficie perfettamente levigata da utilizzare come veicoli per la preparazione di miscele inala
|
|
GB9920839D0
(en)
|
1999-09-04 |
1999-11-10 |
Innovata Biomed Ltd |
Inhaler
|
|
EP1129705A1
(en)
*
|
2000-02-17 |
2001-09-05 |
Rijksuniversiteit te Groningen |
Powder formulation for inhalation
|
|
GB0009469D0
(en)
|
2000-04-17 |
2000-06-07 |
Vectura Ltd |
Improvements in or relating to formalities for use in inhaler devices
|
|
PE20011227A1
(es)
|
2000-04-17 |
2002-01-07 |
Chiesi Farma Spa |
Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
|
|
PL200063B1
(pl)
*
|
2000-10-12 |
2008-12-31 |
Boehringer Ingelheim Pharma |
Nowe proszki do inhalacji zawierające tiotropium
|
|
UA75375C2
(en)
*
|
2000-10-12 |
2006-04-17 |
Boehringer Ingelheim Pharma |
Method for producing powdery preparations for inhaling
|
|
US20060194773A1
(en)
*
|
2001-07-13 |
2006-08-31 |
Paratek Pharmaceuticals, Inc. |
Tetracyline compounds having target therapeutic activities
|
|
DE10141377A1
(de)
*
|
2001-08-23 |
2003-03-13 |
Boehringer Ingelheim Pharma |
Aufstreuverfahren zur Herstellung von Pulverformulierungen
|
|
US8337816B2
(en)
*
|
2001-09-17 |
2012-12-25 |
Glaxo Group Limited |
Dry powder medicament formulations
|
|
CA2466982A1
(en)
*
|
2001-11-19 |
2003-05-30 |
Becton, Dickinson And Company |
Pharmaceutical compositions in particulate form
|
|
GB0128148D0
(en)
|
2001-11-23 |
2002-01-16 |
Innovata Biomed Ltd |
Assembly
|
|
US6900317B2
(en)
*
|
2002-02-19 |
2005-05-31 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Salts of the CGRP antagonist BIBN4096 and inhalable powdered medicaments containing them
|
|
DE10207026A1
(de)
*
|
2002-02-20 |
2003-08-28 |
Boehringer Ingelheim Kg |
Pulverinhalativum, enthaltend den CGRP-Antagonisten BIBN4096 und Verfahren zu dessen Herstellung
|
|
US20040014679A1
(en)
*
|
2002-02-20 |
2004-01-22 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
Inhalation powder containing the CGRP antagonist BIBN4096 and process for the preparation thereof
|
|
JP2006516531A
(ja)
*
|
2002-08-21 |
2006-07-06 |
ノートン ヘルスケアー リミテッド |
吸入組成物
|
|
US7763280B2
(en)
|
2002-11-28 |
2010-07-27 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Tiotropium containing powder formulation for inhalation
|
|
DE10255387A1
(de)
*
|
2002-11-28 |
2004-06-09 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Tiotropium-haltige Pulverformulierung für die Inhalation
|
|
DE10317461A1
(de)
|
2003-04-16 |
2004-10-28 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Radioaktiv markierte Mikropartikel, Verfahren zu deren Herstellung und deren Verwendung
|
|
DE10338407A1
(de)
*
|
2003-08-18 |
2005-03-17 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Inhalationspulver enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazin
|
|
US20050042179A1
(en)
*
|
2003-08-18 |
2005-02-24 |
Boehringer Ingelheim International Gmbh |
Inhalative powder formulations containing the CGRP-antagonist 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine
|
|
US20050042178A1
(en)
*
|
2003-08-18 |
2005-02-24 |
Boehringer Ingelheim International Gmbh |
Microparticles containing the CGRP-antagonist 1-[N2-[3,5-dibrom-N-[[4-(3,4-dihydro-2(1H)-oxoquinazoline-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine, process for preparing and the use thereof as inhalation powder
|
|
DE10338402A1
(de)
*
|
2003-08-18 |
2005-03-17 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Sprühgetrocknetes, amorphes BIBN 4096, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum
|
|
DE10338403A1
(de)
*
|
2003-08-18 |
2005-03-17 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Pulverformulierung, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyrindinyl)-piperazin, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum
|
|
DE10338399A1
(de)
*
|
2003-08-18 |
2005-03-17 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Mikropartikel, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-Iysyl]-4-(4-pyridinyl)-piperazin, Verfahren zu deren Herstellung sowie deren Verwendung als Inhalaltionspulver
|
|
US20050043247A1
(en)
*
|
2003-08-18 |
2005-02-24 |
Boehringer Ingelheim International Gmbh |
Spray-dried amorphous BIBN 4096, process for preparing and the use thereof as inhalative
|
|
CA2575957C
(en)
|
2003-09-02 |
2010-11-30 |
Norton Healthcare Ltd. |
Process for preparing a medicament
|
|
PE20050489A1
(es)
|
2003-11-04 |
2005-09-02 |
Glaxo Group Ltd |
Antagonistas de receptores de acetilcolina muscarinicos
|
|
WO2005102429A1
(en)
|
2004-04-21 |
2005-11-03 |
Innovata Biomed Limited |
Inhaler
|
|
GB0409197D0
(en)
|
2004-04-24 |
2004-05-26 |
Innovata Biomed Ltd |
Device
|
|
UY28871A1
(es)
|
2004-04-27 |
2005-11-30 |
Glaxo Group Ltd |
Antagonistas del receptor de acetilcolina muscarinico
|
|
US7727962B2
(en)
*
|
2004-05-10 |
2010-06-01 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Powder comprising new compositions of oligosaccharides and methods for their preparation
|
|
US7611709B2
(en)
*
|
2004-05-10 |
2009-11-03 |
Boehringer Ingelheim Pharma Gmbh And Co. Kg |
1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives
|
|
US7723306B2
(en)
*
|
2004-05-10 |
2010-05-25 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation
|
|
DE102004048389A1
(de)
*
|
2004-10-01 |
2006-04-06 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Modifizierung von Oberflächen von Laktose als Hilfsstoff zur Verwendung für Pulverinhalativa
|
|
DE102004048390A1
(de)
*
|
2004-10-01 |
2006-04-06 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Pulverinhalativa auf Basis modifizierter Laktosemischungen als Hilfsstoff
|
|
US8298616B2
(en)
|
2008-07-24 |
2012-10-30 |
American Air Liquide, Inc. |
Heteroleptic cyclopentadienyl transition metal precursors for deposition of transition metal-containing films
|
|
US9925282B2
(en)
|
2009-01-29 |
2018-03-27 |
The General Hospital Corporation |
Cromolyn derivatives and related methods of imaging and treatment
|
|
JP5809985B2
(ja)
|
2009-02-26 |
2015-11-11 |
グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ |
４−｛（１ｒ）−２−［（６−｛２−［（２，６−ジクロロベンジル）オキシ］エトキシ｝ヘキシル）アミノ］−１−ヒドロキシエチル｝−２−（ヒドロキシメチル）フェノールを含む医薬製剤
|
|
GB0921075D0
(en)
|
2009-12-01 |
2010-01-13 |
Glaxo Group Ltd |
Novel combination of the therapeutic agents
|
|
PT106094A
(pt)
|
2012-01-13 |
2013-07-15 |
Hovione Farmaciencia S A |
Administração por inalação de formulações com dose elevada
|
|
US20150165038A1
(en)
*
|
2012-02-10 |
2015-06-18 |
Arven llac Sanayi Ve Ticaret A.S. |
Compositions comprising muscarinic receptor antagonist and sorbitol
|
|
WO2014007772A2
(en)
|
2012-07-05 |
2014-01-09 |
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi |
Inhalation compositions comprising glucose anhydrous
|
|
US10105316B2
(en)
|
2012-07-05 |
2018-10-23 |
Arven llac Sanayi Ve Ticaret A.S. |
Inhalation compositions comprising muscarinic receptor antagonist
|
|
WO2014007769A1
(en)
*
|
2012-07-05 |
2014-01-09 |
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi |
Compositions comprising muscarinic receptor antagonist and glucose anhydrous
|
|
US9855276B2
(en)
|
2012-10-25 |
2018-01-02 |
The General Hospital Corporation |
Combination therapies for the treatment of Alzheimer's disease and related disorders
|
|
GB201305825D0
(en)
|
2013-03-28 |
2013-05-15 |
Vectura Ltd |
New use
|
|
US10525005B2
(en)
|
2013-05-23 |
2020-01-07 |
The General Hospital Corporation |
Cromolyn compositions and methods thereof
|
|
JP6529012B2
(ja)
|
2013-10-08 |
2019-06-12 |
エイアイ・セラピューティクス・インコーポレーテッド |
リンパ脈管筋腫症の処置のためのラパマイシン
|
|
AU2014340182B2
(en)
|
2013-10-22 |
2019-05-23 |
The General Hospital Corporation |
Cromolyn derivatives and related methods of imaging and treatment
|
|
NZ724756A
(en)
|
2014-04-04 |
2023-07-28 |
Ai Therapeutics Inc |
An inhalable rapamycin formulation for treating age-related conditions
|
|
AU2015330905B2
(en)
|
2014-10-07 |
2021-02-25 |
AI Therapeutics, Inc. |
An inhalable rapamycin formulation for the treatment of pulmonary hypertension
|
|
EP3506894B1
(en)
|
2016-08-31 |
2023-08-23 |
The General Hospital Corporation |
Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
|
|
MY200258A
(en)
|
2017-06-28 |
2023-12-17 |
Philip Morris Products Sa |
Container with particles for use with inhaler
|
|
WO2019017995A1
(en)
|
2017-07-20 |
2019-01-24 |
Aztherapies, Inc. |
FORMULATIONS OF CROMOLYNE SODIUM POWDER AND IBUPROFEN
|
|
JP2021529771A
(ja)
|
2018-07-02 |
2021-11-04 |
ザ ジェネラル ホスピタル コーポレイション |
クロモリンナトリウムおよびα−ラクトースの粉末製剤
|
|
ES2953293T3
(es)
|
2018-08-07 |
2023-11-10 |
Norton Waterford Ltd |
Aplicación de espectroscopia Raman para la fabricación de polvos para inhalación
|
|
US12383528B2
(en)
|
2018-12-10 |
2025-08-12 |
The General Hospital Corporation |
Cromolyn esters and uses thereof
|
|
JP2023520580A
(ja)
|
2020-04-06 |
2023-05-17 |
ザ ジェネラル ホスピタル コーポレイション |
コロナウイルス誘発炎症状態の処置方法
|
|
WO2022043481A1
(en)
|
2020-08-28 |
2022-03-03 |
Universität Linz |
Use of leoligin in the prevention of tissue damage
|
|
WO2022146914A1
(en)
|
2020-12-28 |
2022-07-07 |
The General Hospital Corporation |
Cromolyn derivatives and uses thereof
|
|
WO2026002967A1
(en)
|
2024-06-24 |
2026-01-02 |
Universität Linz |
Leoligin and derivatives thereof as calcium channel blockers for the prevention and/or treatment of related diseases
|